Vimarsana
Biggest News Aggregation in the World

Page 7 - Agent Capital News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Agent Capital. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Agent Capital Today - Breaking & Trending Today

Investegate |Zenas BioPharma Announcements | Zenas BioPharma: Zenas BioPharma Secures $118 Million to Advance Its Broad Pipeline of Autoimmune Disease Therapeutics - Vimarsana News

Investegate |Zenas BioPharma Announcements | Zenas BioPharma: Zenas BioPharma Secures $118 Million to Advance Its Broad Pipeline of Autoimmune Disease Therapeutics

Investegate announcements from Zenas BioPharma, Zenas BioPharma Secures $118 Million to Advance Its Broad Pipeline of Autoimmune Disease Therapeutics

Zenas BioPharma Secures $118 Million to Advance Its Broad Pipeline of Autoimmune Disease Therapeutics - Vimarsana News

Zenas BioPharma Secures $118 Million to Advance Its Broad Pipeline of Autoimmune Disease Therapeutics

Proceeds to fund global Phase 3 registration program for the company's lead product candidate, Obexelimab, and support the clinical development of other pipeline programsSeries B equity financing led by

BBCNEWS Breakfast June 4, 2024 06:13:00 - Vimarsana News

BBCNEWS Breakfast June 4, 2024 06:13:00

Today the king and queen consort will attend their first joint public engagement, marking the end of the royal period of mourning for the late queen. the couple will visit dunfermline in fife as part of the celebrations to mark its new city status. our scotland correspondent lorna gordon is in dunfermline for us. what can we expect today? it is a bi da what can we expect today? it is a big day for— what can we expect today? it is a big day for dunfermline, - what can we expect today? it is a i big day for dunfermline, scotland's agent capital becomes scotland's newest city. it is king charle...

With a pending $30M investment, Carisma Therapeutics merges with Boston-based Sesen Bio - Vimarsana News

With a pending $30M investment, Carisma Therapeutics merges with Boston-based Sesen Bio

The combined company will operate under Carisma's name, and will work on advancing Carisma’s proprietary cell therapy platform.

Immunitas Cleared by FDA to Begin Trial of IMT-009 in Hematologic Malignancies, Solid Tumors - Vimarsana News

Immunitas Cleared by FDA to Begin Trial of IMT-009 in Hematologic Malignancies, Solid Tumors

The firm will use a biomarker strategy in its Phase I/II clinical trial to evaluate responses to therapy and inform future patient selection.